↓ Skip to main content

The development of bispecific antibodies and their applications in tumor immune escape

Overview of attention for article published in Experimental Hematology & Oncology, May 2017
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#33 of 183)
  • Good Attention Score compared to outputs of the same age (68th percentile)

Mentioned by

twitter
4 tweeters
patent
1 patent

Citations

dimensions_citation
66 Dimensions

Readers on

mendeley
121 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The development of bispecific antibodies and their applications in tumor immune escape
Published in
Experimental Hematology & Oncology, May 2017
DOI 10.1186/s40164-017-0072-7
Pubmed ID
Authors

Xiaolong Zhang, Yuanyuan Yang, Dongmei Fan, Dongsheng Xiong

Abstract

During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites. Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clinical development. Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 <1%
Unknown 120 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 19%
Student > Bachelor 18 15%
Other 16 13%
Student > Ph. D. Student 14 12%
Student > Master 14 12%
Other 15 12%
Unknown 21 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 30 25%
Agricultural and Biological Sciences 18 15%
Medicine and Dentistry 16 13%
Immunology and Microbiology 15 12%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Other 14 12%
Unknown 22 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2018.
All research outputs
#4,924,509
of 18,166,797 outputs
Outputs from Experimental Hematology & Oncology
#33
of 183 outputs
Outputs of similar age
#84,885
of 274,375 outputs
Outputs of similar age from Experimental Hematology & Oncology
#1
of 1 outputs
Altmetric has tracked 18,166,797 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 183 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,375 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them